Adjuvant Therapy in "Intermediate-Risk" Early-Stage Cervical Cancer: To Treat or Not to Treat? Systematic Review and Meta-Analysis.

ABSTRACT: International guidelines do not take a clear position regarding the management of patients with "intermediate-risk" cervical cancer, and they remain noncommittal on the necessity of adjuvant therapy following radical hysterectomy. To determine if adjuvant therapy after surgery adds benefit in "intermediate-risk" cervical cancer patients in terms of recurrence rate and mortality rate, we performed a systematic review with meta-analysis on Google Scholar, PubMed, and Scopus. The inclusion criteria were studies with >100 patients with intermediate-risk cervical cancer according to the Sedlis criteria, RCTs, or propensity score-matched cohort studies reporting oncological outcomes and treatment-related toxicity, comparing a surgery-only cohort with an adjuvant therapy cohort. We found 11 studi

SUBMITTER: Ripepi C 

PROVIDER: S-EPMC12026193 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature